EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today the initiation of a second Phase 2 study of ADL5859, a novel delta opioid agonist in development for the treatment of pain. Study 33CL232 will explore the analgesic efficacy of ADL5859 in treating inflammatory pain associated with rheumatoid arthritis.
“This study represents an important component of our ongoing program to assess our delta agonists across a number of pain conditions,” said Michael R. Dougherty, president and chief executive officer of Adolor Corporation. “We believe there is a significant need for novel medicines to treat a variety of pain states, and are pleased to now begin our second Phase 2 study with ADL5859.”
